Obesity Patient Survey Are you 18 years of age or older and living with obesity? Managing associated weight-related issues is challenging. Take this survey to let us know your opinions and outlook on living with and managing this common, chronic disease. The Gastrointestinal Society and the Canadian Society of Intestinal Research represent patients on a [...]
Health Canada: Mesalazine Caution: Health Canada released a statement on 2020-09-23 indicating it has reviewed the potential risk of birth defects in babies associated with the use of mesalazine-containing products in pregnant women who were using these products to treat inflammatory bowel disease (primarily Crohn's disease and ulcerative colitis). Health Canada conducted a safety review [...]
Gaps in Care and Awareness of Fecal Microbiota Transplant for C. difficile The Canadian Agency for Drugs and Technologies in Health (CADTH) launched a research project to determine how Canadian patients access fecal microbiota transplant (FMT). Currently, fecal transplant is approved in Canada as an alternative treatment for recurring Clostridioides difficile infection (formerly known as [...]
GI Society and CSIR Provide Input to PMPRB Consultations On August 4, 2020, the Gastrointestinal Society and its partner charity, the Canadian Society of Intestinal Research, provided input on the Patented Medicine Prices Review Board (PMPRB) 2020 Draft Guidelines. These Guidelines are part of a broad set of regulatory changes sought by the PMPRB to [...]
Access to Innovative Medicines for Canadian Patients The Gastrointestinal Society continues to advocate for system-wide improvements in care and treatment for people with GI and liver diseases and disorders, ensuring that all patients have affordable and timely access to appropriate healthcare and medication. As part of this mandate, we have actively been involved in consultations [...]
Canadian Charities Need the Government's Support to Survive the COVID-19 Crisis Due to the COVID-19 crisis, the survival of Canadian charities is at risk. This is why the Gastrointestinal Society has joined 150 of Canada’s leading charities to call on the Federal Government for emergency support. Charities are a vital part of the Canadian economy, [...]
January 29, 2020 Gail Attara President & Chief Executive Officer, Gastrointestinal Society President, Canadian Society of Intestinal Research Forced Switching Policies: Will Ontario be Next? Government-led initiatives have never shown us so clearly how invasive their roles can become in the determination of our healthcare treatments. “Life in the hands of your doctor not the [...]
C. diff Survey Results: Published Research Between the spring and autumn of 2016, the GI Society hosted a survey on our English and French websites to help understand how CDI affects people. Thank you to everyone who shared your experiences with us by participating in this survey. Your opinions are very important to us and [...]
Short-sighted policies, clickbait savings, and long-term damage to IBD patients December 18, 2019 Gail Attara President & Chief Executive Officer, Gastrointestinal Society President, Canadian Society of Intestinal Research Alberta’s policy decision to switch the treatments of thousands of patients to biosimilars comes under the guise of presumed cost-savings and at the behest of a [...]
IBD Patients: What's Missing in Your Care? We invite you to take part in this survey about communication between patients and their physicians regarding inflammatory bowel disease (primarily Crohn’s disease and ulcerative colitis). This is a follow-up to a survey we conducted in 2018 about the unmet need in inflammatory bowel disease and we are [...]
